Drug intelligence / Profile preview

Q-1806

Development stage: Preclinical
Lead developer: QureBio
Modality: Trispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics

Overview

Q-1806 is a trispecific antibody developed by QureBio that targets three key molecules implicated in cancer progression: beta-nerve growth factor (NGFB), programmed death-ligand 1 (PDL1), and vascular endothelial growth factor (VEGF). Its mechanism of action involves simultaneous inhibition of NGFB, PDL1, and VEGF gene activity. By blocking these pathways, Q-1806 aims to suppress tumor growth, angiogenesis, and immune evasion. The drug is being investigated for the treatment of neoplasms (cancers) and is currently in preclinical development[1][3][7].

Targets

NGF (Nerve growth factor)CD274 (Programmed cell death protein 1 ligand 1)VEGFA (Vascular endothelial growth factor A)

Beyond the preview

Go deeper on Q-1806.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Q-1806.

Explore the full profile